ClinicalTrials.gg
CompletedNCT00887484Updated Dec 13, 2016Results posted

A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne

A Phase 4 interventional study of BENZOYL PEROXIDE/ CLINDAMYCIN and BENZOYL PEROXIDE/ ADAPALENE in Acne Vulgaris, sponsored by Stiefel, a GSK Company. Completed at 4 sites in Argentina. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2016-12-13.

Sponsored by Stiefel, a GSK Company (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing Benzoyl Peroxide in Acne Vulgaris — none open to participants now, 1 under way, none of them phase 3. Benzoyl Peroxide · Acne Vulgaris.

Enrollment
24th of 33
50 · median 90
Started
2009
with 5 others
Phase 4
16 of 33
none open now
Registered
12th of 33
by date
Lead sponsor
7 of 33
Stiefel, a GSK Company

Among the 33 studies testing Benzoyl Peroxide in Acne Vulgaris, this one is the 24th largest by enrollment, is one of 6 that started in 2009, is one of 16 in phase 4, and was the 12th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 33 studies testing Benzoyl Peroxide in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About Benzoyl Peroxide

Benzoyl Peroxide: first FDA approval 1984 (BENZAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing Benzoyl Peroxide in Acne Vulgaris as a file.
02

Study summary

The purpose of this study is to compare the tolerability of topical combination therapies in the treatment of facial acne.

Read the detailed description

The purpose of this study is to compare the tolerability of topical combination therapies in the treatment of facial acne.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Acne
  • Acne Vulgaris
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects at least 21 years of age, in good general health with documented diagnosis of acne vulgaris.
  • Female subjects of must have a negative pregnancy test. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of Abstinence is considered an acceptable method of contraception.
  • Inflammatory (papules and pustules) and non-inflammatory (open and closed comedones) facial lesions.
  • The ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study
  • Capable of understanding and willing to provide signed and dated written voluntary (and any local or national authorization requirements) before any protocol specific procedures are performed

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant, trying to become pregnant or breastfeeding.
  • Subjects who have any finding at their baseline physical other than acne vulgaris.
  • History or presence of regional enteritis or inflammatory bowel disease (eg, ulcerative colitis, pseudomembranous colitis, chronic diarrhea, or a history of antibiotic-associated colitis) or similar symptoms.
  • Use of topical antibiotics or anti-acne medications on the face and systemic antibiotics within the past 2 and 4 weeks, respectively.
  • Use of topical on the face or systemic corticosteroids within the past 4 weeks. Use of inhaled, intra-articular or intra-lesional (other than for facial acne lesions) steroids is acceptable.
  • Use of systemic retinoids within the past 6 months.
  • Facial procedures performed by an esthetician, beautician, physician, nurse, or other practitioner, within the past 4 weeks or during the conduct of the study.
  • Known or previous allergic reaction to any of the active components, lincomycin, adapalene, clindamycin, benzoyl peroxide or of the study product.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Clindoxyl Gel

    Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.

    Drug: BENZOYL PEROXIDE/ CLINDAMYCIN

  • Active comparator
    Epiduo gel

    Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.

    Drug: BENZOYL PEROXIDE/ ADAPALENE

Interventions

  • DrugBENZOYL PEROXIDE/ CLINDAMYCIN

    Drug pages: Benzoyl Peroxide · Clindamycin

    Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.

  • DrugBENZOYL PEROXIDE/ ADAPALENE

    Drug pages: Benzoyl Peroxide · Adapalene

    Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.

06

What researchers measure

Primary outcomes

  1. Erythema (Redness)

    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.

    Time frame: Weeks 1 and 2

  2. Skin Dryness

    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.

    Time frame: Weeks 1 and 2

  3. Skin Peeling

    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3,Intense.

    Time frame: Weeks 1 and 2

  4. Irritant/Allergic Contact Dermatitis

    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.

    Time frame: Weeks 1 and 2

Secondary outcomes

  1. Erythema (Redness)

    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.

    Time frame: Weeks 5 and 8

  2. Skin Dryness

    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.

    Time frame: Weeks 5 and 8

  3. Skin Peeling

    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.

    Time frame: Weeks 5 and 8

  4. Irritant/Allergic Contact Dermatitis

    Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.

    Time frame: Weeks 5 and 8

  5. Investigators Static Global Assessment

    ISGA is evaluated using the following scale: 0, Clear: Clear skin with no lesions; 1, Almost Clear: Rare non-inflammatory lesions; 2, Mild: Some non-inflammatory lesions with no more than a few inflammatory lesions but no nodular lesions); 3, Moderate: Up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 small nodular lesion; 4, Severe: Up to many non-inflammatory and inflammatory lesions, but no more than a few nodular lesions; 5, Very Severe: Many non-inflammatory and inflammatory lesions and more than a few nodular lesions. May have cystic lesions.

    Time frame: Baseline, Weeks 5, 8

  6. Total Acne Lesion Counts

    Total acne lesion counts - includes both inflammatory acne lesions (pustules, papules), noninflammatory lesions (whiteheads and blackheads),

    Time frame: Baseline, Weeks 5 and 8

  7. Inflammatory Acne Lesion Counts

    Total number of inflammatory acne lesions (pustules, papules) at each timepoint.

    Time frame: Baseline, Weeks 5 and 8

  8. Non-inflammatory Acne Lesion Counts

    Total number of non-inflammatory acne lesions (whiteheads and blackheads) at each timepoint.

    Time frame: Baseline, Weeks 5 and 8

  9. Skindex-29 Quality of Life Questionnaire (QoL) - Symptomatic Domain

    Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The symptomatic score (score=0 to 28)=(sum of the 7 individual item scores) \* 100/28.

    Time frame: Baseline, Weeks 2 and 8

  10. Quality of Life Questionnaire - Emotional Domain

    Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The emotional score (score=0 to 40)=(sum of the 10 individual item scores) \* 100/40.

    Time frame: Baseline, Weeks 2 and 8

  11. Quality of Life Questionnaire - Functional Domain

    Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The functional score (score=0 to 48)=(sum of the 12 individual item scores) \* 100/48.

    Time frame: Baseline, Weeks 2 and 8

  12. Quality of Life Questionnaire - Global Score

    Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. A Global Score (range 0-100)=(sum of all 29 individual item scores) \* 100/116.

    Time frame: Baseline, Weeks 2 and 8

  13. Product Acceptability and Preference Questionnaire - Severity of Redness at Weeks 1 and 2

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

    Time frame: Weeks 1 and 2

  14. Product Acceptability and Preference Questionnaire - Severity of Redness at Week 8

    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

    Time frame: Week 8

  15. Product Acceptability and Preference Questionnaire - Severity of Dryness at Weeks 1 and 2

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

    Time frame: Weeks 1 and 2

  16. Product Acceptability and Preference Questionnaire - Severity of Dryness at Week 8

    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

    Time frame: Week 8

  17. Product Acceptability and Preference Questionnaire - Severity of Burning at Weeks 1 and 2

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

    Time frame: Weeks 1 and 2

  18. Product Acceptability and Preference Questionnaire - Severity of Burning at Week 8

    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

    Time frame: Week 8

  19. Product Acceptability and Preference Questionnaire - Severity of Itching at Weeks 1 and 2

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

    Time frame: Weeks 1 and 2

  20. Product Acceptability and Preference Questionnaire - Severity of Itching at Week 8

    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

    Time frame: Week 8

  21. Product Acceptability and Preference Questionnaire - Severity of Scaling at Weeks 1 and 2

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.

    Time frame: Weeks 1 and 2

  22. Product Acceptability and Preference Questionnaire - Severity of Scaling at Week 8

    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.

    Time frame: Week 8

  23. Product Acceptability and Preference Questionnaire - Ease of Application of Product at Weeks 1 and 2

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.

    Time frame: Weeks 1 and 2

  24. Product Acceptability and Preference Questionnaire - Ease of Application of Product at Week 8

    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.

    Time frame: Week 8

  25. Product Acceptability and Preference Questionnaire - Comfort of Skin at Weeks 1 and 2

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.

    Time frame: Weeks 1 and 2

  26. Product Acceptability and Preference Questionnaire - Comfort of Skin at Week 8

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.

    Time frame: Week 8

  27. Product Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With? at Weeks 1 and 2

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following choices: Epiduo, Clindoxyl Gel, Both Treatments Equally.

    Time frame: Weeks 1 and 2

  28. Product Acceptability and Preference Questionnaire - Comparison of Study Products Used in the Past at Week 8

    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, More Satisfied; 2, Somewhat More Satisfied; 3, Neither Satisfied or Dissatisfied; 4, Somewhat More Dissatisfied; 5, More Dissatisfied.

    Time frame: Week 8

  29. Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Weeks 1 and 2

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, Uncomfortable.

    Time frame: Weeks 1 and 2

  30. Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Week 8

    Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, More Dissatisfied.

    Time frame: Week 8

  31. Product Acceptability and Preference Questionnaire - Compliance at Weeks 1 and 2

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Compliant at all; 1, Mostly Compliant; 2, Very Compliant.

    Time frame: Weeks 1 and 2

  32. Product Acceptability and Preference Questionnaire - Compliance at Week 8

    Product Acceptability and Preference Questionnaire were completed by the subject at week 8 by answering Yes or No to the following question: Did you use the product every day?. When only one product was applied to the face, subjects were asked to rate their compliance by answering the aforementioned question, rather than rating compliance on a 0-2 scale.

    Time frame: Week 8

  33. Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Weeks 1 and 2

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?

    Time frame: Weeks 1 and 2

  34. Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Week 8

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?

    Time frame: Week 8

  35. Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 1 and 2

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?

    Time frame: Weeks 1 and 2

  36. Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 8

    Product Acceptability and Preference Questionnaire were completed by the subject at 8 week timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?

    Time frame: Week 8

  37. Product Acceptability and Preference Questionnaire - Ease of Use Wtih Make-Up at Weeks 1 and 2

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.

    Time frame: Weeks 1 and 2

  38. Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up at Week 8

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.

    Time frame: Week 8

  39. Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Weeks 1 and 2

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.

    Time frame: Weeks 1 and 2

  40. Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Week 8

    Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.

    Time frame: Week 8

07

Results

Posted Oct 23, 2012

Participant flow

Clinical research center

Split Face Treatment (Weeks 1 and 2)
Participant flow — Split Face Treatment (Weeks 1 and 2)
MilestoneClindoxyl and Epiduo Gels
Started48
Completed48
Not completed0
Full Face Treatment (Weeks 5 and 8)
Participant flow — Full Face Treatment (Weeks 5 and 8)
MilestoneClindoxyl and Epiduo Gels
Started48
Completed45
Not completed3
Withdrew: Adverse event1
Withdrew: Lost to follow-up1
Withdrew: Pregnancy1

Outcome measures

PrimaryErythema (Redness)

Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.

Time frame:
Weeks 1 and 2
Reported as:
Mean · units on a scale
Erythema (Redness)
units on a scaleClindoxyl GelEpiduo Gel
Week 10.66 ± 0.700.91 ± 0.78
Week 20.55 ± 0.620.74 ± 0.64
SecondaryErythema (Redness)

Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.

Time frame:
Weeks 5 and 8
Reported as:
Mean · units on a scale
Erythema (Redness)
units on a scaleClindoxyl Gel
Week 50.22 ± 0.42
Week 80.19 ± 0.50
SecondarySkin Dryness

Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.

Time frame:
Weeks 5 and 8
Reported as:
Mean · units on a scale
Skin Dryness
units on a scaleClindoxyl Gel
Week 50.20 ± 0.46
Week 80.04 ± 0.29
PrimarySkin Dryness

Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.

Time frame:
Weeks 1 and 2
Reported as:
Mean · units on a scale
Skin Dryness
units on a scaleClindoxyl GelEpiduo Gel
Week 10.47 ± 0.550.96 ± 0.75
Week 20.40 ± 0.580.64 ± 0.74
PrimarySkin Peeling

Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3,Intense.

Time frame:
Weeks 1 and 2
Reported as:
Mean · units on a scale
Skin Peeling
units on a scaleClindoxyl GelEpiduo
Week 10.34 ± 0.520.68 ± 0.78
Week 20.40 ± 0.610.60 ± 0.68
PrimaryIrritant/Allergic Contact Dermatitis

Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.

Time frame:
Weeks 1 and 2
Reported as:
Mean · units on a scale
Irritant/Allergic Contact Dermatitis
units on a scaleClindoxyl GelEpiduo Gel
Week 10.04 ± 0.200.04 ± 0.20
Week 20.04 ± 0.200.04 ± 0.20
SecondarySkin Peeling

Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.

Time frame:
Weeks 5 and 8
Reported as:
Mean · units on a scale
Skin Peeling
units on a scaleClindoxyl Gel
Week 50.13 ± 0.40
Week 80.06 ± 0.25
SecondaryIrritant/Allergic Contact Dermatitis

Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face. Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.

Time frame:
Weeks 5 and 8
Reported as:
Mean · units on a scale
Irritant/Allergic Contact Dermatitis
units on a scaleClindoxyl Gel
Week 50.00 ± 0.00
Week 80.00 ± 0.00
SecondaryInvestigators Static Global Assessment

ISGA is evaluated using the following scale: 0, Clear: Clear skin with no lesions; 1, Almost Clear: Rare non-inflammatory lesions; 2, Mild: Some non-inflammatory lesions with no more than a few inflammatory lesions but no nodular lesions); 3, Moderate: Up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 small nodular lesion; 4, Severe: Up to many non-inflammatory and inflammatory lesions, but no more than a few nodular lesions; 5, Very Severe: Many non-inflammatory and inflammatory lesions and more than a few nodular lesions. May have cystic lesions.

Time frame:
Baseline, Weeks 5, 8
Reported as:
Mean · units on a scale
Investigators Static Global Assessment
units on a scaleClindoxyl Gel
Baseline2.77 ± 0.56
Week 51.89 ± 0.75
Week 81.62 ± 0.92
SecondaryTotal Acne Lesion Counts

Total acne lesion counts - includes both inflammatory acne lesions (pustules, papules), noninflammatory lesions (whiteheads and blackheads),

Time frame:
Baseline, Weeks 5 and 8
Reported as:
Mean · Acne Lesions
Total Acne Lesion Counts
Acne LesionsClindoxyl Gel
Baseline39.06 ± 12.95
Week 515.96 ± 10.37
Week 813.77 ± 11.50
SecondaryInflammatory Acne Lesion Counts

Total number of inflammatory acne lesions (pustules, papules) at each timepoint.

Time frame:
Baseline, Weeks 5 and 8
Reported as:
Mean · Acne Lesions
Inflammatory Acne Lesion Counts
Acne LesionsClindoxyl Gel
Baseline14.23 ± 9.06
Week 54.60 ± 3.93
Week 84.26 ± 5.84
SecondaryNon-inflammatory Acne Lesion Counts

Total number of non-inflammatory acne lesions (whiteheads and blackheads) at each timepoint.

Time frame:
Baseline, Weeks 5 and 8
Reported as:
Mean · Acne Lesions
Non-inflammatory Acne Lesion Counts
Acne LesionsClindoxyl Gel
Baseline24.83 ± 12.84
Week 511.36 ± 7.89
Week 89.51 ± 8.53
SecondarySkindex-29 Quality of Life Questionnaire (QoL) - Symptomatic Domain

Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The symptomatic score (score=0 to 28)=(sum of the 7 individual item scores) \* 100/28.

Time frame:
Baseline, Weeks 2 and 8
Reported as:
Mean · Units on a scale
Skindex-29 Quality of Life Questionnaire (QoL) - Symptomatic Domain
Units on a scaleClindoxyl Gel
Baseline20.91 ± 15.73
Week 221.58 ± 14.17
Week 813.75 ± 14.03
SecondaryQuality of Life Questionnaire - Emotional Domain

Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The emotional score (score=0 to 40)=(sum of the 10 individual item scores) \* 100/40.

Time frame:
Baseline, Weeks 2 and 8
Reported as:
Mean · Units on a scale
Quality of Life Questionnaire - Emotional Domain
Units on a scaleClindoxyl Gel
Baseline25.32 ± 19.73
Week 219.38 ± 18.68
Week 816.42 ± 19.08
SecondaryQuality of Life Questionnaire - Functional Domain

Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The functional score (score=0 to 48)=(sum of the 12 individual item scores) \* 100/48.

Time frame:
Baseline, Weeks 2 and 8
Reported as:
Mean · Units on a scale
Quality of Life Questionnaire - Functional Domain
Units on a scaleClindoxyl Gel
Baseline8.59 ± 13.98
Week 26.30 ± 11.77
Week 85.19 ± 11.78
SecondaryQuality of Life Questionnaire - Global Score

Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. A Global Score (range 0-100)=(sum of all 29 individual item scores) \* 100/116.

Time frame:
Baseline, Weeks 2 and 8
Reported as:
Mean · Units on a scale
Quality of Life Questionnaire - Global Score
Units on a scaleClindoxyl Gel
Baseline8.59 ± 13.98
Week 26.30 ± 11.77
Week 85.19 ± 11.78
SecondaryProduct Acceptability and Preference Questionnaire - Severity of Redness at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

Time frame:
Weeks 1 and 2
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Severity of Redness at Weeks 1 and 2
Units on a scaleClindoxyl GelEpiduo Gel
Week 11.09 ± 1.181.72 ± 1.21
Week 20.72 ± 0.861.15 ± 1.07
SecondaryProduct Acceptability and Preference Questionnaire - Severity of Redness at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

Time frame:
Week 8
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Severity of Redness at Week 8
Units on a scaleClindoxyl Gel
Product Acceptability and Preference Questionnaire - Severity of Redness at Week 80.77 ± 1.09
SecondaryProduct Acceptability and Preference Questionnaire - Severity of Dryness at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

Time frame:
Weeks 1 and 2
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Severity of Dryness at Weeks 1 and 2
Units on a scaleClindoxyl GelEpiduo Gel
Week 11.30 ± 1.141.81 ± 1.14
Week 21.00 ± 0.871.41 ± 1.17
SecondaryProduct Acceptability and Preference Questionnaire - Severity of Dryness at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

Time frame:
Week 8
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Severity of Dryness at Week 8
Units on a scaleClindoxyl Gel
Product Acceptability and Preference Questionnaire - Severity of Dryness at Week 80.64 ± 0.97
SecondaryProduct Acceptability and Preference Questionnaire - Severity of Burning at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

Time frame:
Weeks 1 and 2
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Severity of Burning at Weeks 1 and 2
Units on a scaleClindoxyl GelEpiduo Gel
Week 10.91 ± 1.231.68 ± 1.20
Week 20.72 ± 0.891.30 ± 1.23
SecondaryProduct Acceptability and Preference Questionnaire - Severity of Burning at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

Time frame:
Week 8
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Severity of Burning at Week 8
Units on a scaleClindoxyl Gel
Product Acceptability and Preference Questionnaire - Severity of Burning at Week 80.36 ± 0.76
SecondaryProduct Acceptability and Preference Questionnaire - Severity of Itching at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

Time frame:
Weeks 1 and 2
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Severity of Itching at Weeks 1 and 2
Units on a scaleClindoxyl GelEpiduo Gel
Week 10.64 ± 1.111.02 ± 1.34
Week 20.72 ± 0.960.93 ± 1.00
SecondaryProduct Acceptability and Preference Questionnaire - Severity of Itching at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.

Time frame:
Week 8
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Severity of Itching at Week 8
Units on a scaleClindoxyl Gel
Product Acceptability and Preference Questionnaire - Severity of Itching at Week 80.26 ± 0.49
SecondaryProduct Acceptability and Preference Questionnaire - Severity of Scaling at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.

Time frame:
Weeks 1 and 2
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Severity of Scaling at Weeks 1 and 2
Units on a scaleClindoxyl GelEpiduo Gel
Week 10.79 ± 1.181.43 ± 1.41
Week 20.59 ± 0.691.04 ± 1.07
SecondaryProduct Acceptability and Preference Questionnaire - Severity of Scaling at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.

Time frame:
Week 8
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Severity of Scaling at Week 8
Units on a scaleClindoxyl Gel
Product Acceptability and Preference Questionnaire - Severity of Scaling at Week 80.45 ± 0.83
SecondaryProduct Acceptability and Preference Questionnaire - Ease of Application of Product at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.

Time frame:
Weeks 1 and 2
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Ease of Application of Product at Weeks 1 and 2
Units on a scaleClindoxyl GelEpiduo Gel
Week 11.30 ± 0.511.32 ± 0.56
Week 21.35 ± 0.531.39 ± 0.61
SecondaryProduct Acceptability and Preference Questionnaire - Ease of Application of Product at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.

Time frame:
Week 8
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Ease of Application of Product at Week 8
Units on a scaleClindoxyl Gel
Product Acceptability and Preference Questionnaire - Ease of Application of Product at Week 81.26 ± 0.44
SecondaryProduct Acceptability and Preference Questionnaire - Comfort of Skin at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.

Time frame:
Weeks 1 and 2
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Comfort of Skin at Weeks 1 and 2
Units on a scaleClindoxyl GelEpiduo Gel
Week 12.81 ± 0.883.15 ± 1.08
Week 22.39 ± 0.932.67 ± 0.94
SecondaryProduct Acceptability and Preference Questionnaire - Comfort of Skin at Week 8

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.

Time frame:
Week 8
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Comfort of Skin at Week 8
Units on a scaleClindoxyl Gel
Product Acceptability and Preference Questionnaire - Comfort of Skin at Week 81.83 ± 0.92
SecondaryProduct Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With? at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following choices: Epiduo, Clindoxyl Gel, Both Treatments Equally.

Time frame:
Weeks 1 and 2
Reported as:
Number · Participants
Product Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With? at Weeks 1 and 2
ParticipantsAll Subjects
Week 1, Epiduo Gel, n=4715
Week 1, Clindoxyl Gel, n=4730
Week 1, Both Treatments Equally, n=472
Week 2, Epiduo Gel, n=4616
Week 2, Clindoxyl Gel, n=4629
Week 2, Both Treatments Equally, n=461
SecondaryProduct Acceptability and Preference Questionnaire - Comparison of Study Products Used in the Past at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, More Satisfied; 2, Somewhat More Satisfied; 3, Neither Satisfied or Dissatisfied; 4, Somewhat More Dissatisfied; 5, More Dissatisfied.

Time frame:
Week 8
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Comparison of Study Products Used in the Past at Week 8
Units on a scaleClindoxyl Gel
Product Acceptability and Preference Questionnaire - Comparison of Study Products Used in the Past at Week 81.63 ± 1.08
SecondaryProduct Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, Uncomfortable.

Time frame:
Weeks 1 and 2
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Weeks 1 and 2
Units on a scaleClindoxyl GelEpiduo Gel
Week 11.87 ± 0.682.04 ± 0.78
Week 21.85 ± 0.842.00 ± 0.70
SecondaryProduct Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Week 8

Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, More Dissatisfied.

Time frame:
Week 8
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Week 8
Units on a scaleClindoxyl Gel
Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Week 81.53 ± 0.65
SecondaryProduct Acceptability and Preference Questionnaire - Compliance at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Compliant at all; 1, Mostly Compliant; 2, Very Compliant.

Time frame:
Weeks 1 and 2
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Compliance at Weeks 1 and 2
Units on a scaleClindoxyl GelEpiduo Gel
Week 11.91 ± 0.281.91 ± 0.28
Week 21.85 ± 0.421.85 ± 0.42
SecondaryProduct Acceptability and Preference Questionnaire - Compliance at Week 8

Product Acceptability and Preference Questionnaire were completed by the subject at week 8 by answering Yes or No to the following question: Did you use the product every day?. When only one product was applied to the face, subjects were asked to rate their compliance by answering the aforementioned question, rather than rating compliance on a 0-2 scale.

Time frame:
Week 8
Reported as:
Number · Participants
Product Acceptability and Preference Questionnaire - Compliance at Week 8
ParticipantsClindoxyl Gel
Yes43
No3
SecondaryProduct Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?

Time frame:
Weeks 1 and 2
Reported as:
Number · Participants
Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Weeks 1 and 2
ParticipantsClindoxyl GelEpiduo Gel
Week 1 - Yes1612
Week 1 - No3135
Week 2 - Yes1411
Week 2 - No3235
SecondaryProduct Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Week 8

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?

Time frame:
Week 8
Reported as:
Number · Participants
Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Week 8
ParticipantsClindoxyl Gel
Yes28
No18
SecondaryProduct Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?

Time frame:
Weeks 1 and 2
Reported as:
Number · Participants
Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 1 and 2
ParticipantsClindoxyl GelEpiduo Gel
Week 1 - Yes4426
Week 1 - No321
Week 2 - Yes3932
Week 2 - No714
SecondaryProduct Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 8

Product Acceptability and Preference Questionnaire were completed by the subject at 8 week timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?

Time frame:
Week 8
Reported as:
Number · Participants
Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 8
ParticipantsClindoxyl Gel
Yes41
No5
SecondaryProduct Acceptability and Preference Questionnaire - Ease of Use Wtih Make-Up at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.

Time frame:
Weeks 1 and 2
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Ease of Use Wtih Make-Up at Weeks 1 and 2
Units on a scaleClindoxyl GelEpiduo Gel
Week 12.23 ± 1.242.31 ± 1.38
Week 21.75 ± 0.931.75 ± 0.93
SecondaryProduct Acceptability and Preference Questionnaire - Ease of Use With Make-Up at Week 8

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.

Time frame:
Week 8
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up at Week 8
Units on a scaleClindoxyl Gel
Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up at Week 81.69 ± 0.87
SecondaryProduct Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Weeks 1 and 2

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.

Time frame:
Weeks 1 and 2
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Weeks 1 and 2
Units on a scaleClindoxyl GelEpiduo Gel
Week 12.09 ± 0.692.23 ± 0.87
Week 21.76 ± 0.771.98 ± 0.68
SecondaryProduct Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Week 8

Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.

Time frame:
Week 8
Reported as:
Mean · Units on a scale
Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Week 8
Units on a scaleClindoxyl Gel
Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Week 81.61 ± 0.98

Adverse events

Collected over Baseline through Week 8.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Clindoxyl and Epiduo Gels—0/48 (0%)44/48 (91.7%)
Most frequent other events
Most frequent other events
EventClindoxyl and Epiduo Gels
Application site irritationSkin and subcutaneous tissue disorders36/48
Application site drynessSkin and subcutaneous tissue disorders19/48
Application site pruritusSkin and subcutaneous tissue disorders11/48
Application site exfoliationSkin and subcutaneous tissue disorders10/48
Drug intoleranceSkin and subcutaneous tissue disorders4/48

Baseline characteristics

Age, Continuous
Age, Continuous(years)Clindoxyl and Epiduo Gels
Mean27.6 ± 5.5
Gender
Gender(Participants)Clindoxyl and Epiduo Gels
Female10
Male38
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Clindoxyl and Epiduo Gels
Hispanic or Latino33
Not Hispanic or Latino15
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Clindoxyl and Epiduo Gels
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White48
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Clindoxyl and Epiduo Gels
Argentina48
Investigators Static Global Assessment (ISGA)
Investigators Static Global Assessment (ISGA)(Participants)Clindoxyl and Epiduo Gels
Mild14
Moderate31
Severe3
Inflammatory Acne Lesion Count
Inflammatory Acne Lesion Count(Inflammatory lesions)Clindoxyl and Epiduo Gels
Mean14.2 ± 9.1
Non-Inflammatory Acne Lesion Count
Non-Inflammatory Acne Lesion Count(Non-Infammatory acne lesions)Clindoxyl and Epiduo Gels
Mean24.8 ± 12.8

1 further baseline measures are reported on the registry.

08

Study locations

4 sites
  • Centro de Investigación y Prevencion de Enfermidades Cardiovasculares
    Ciudad Autonoma de Buenos Aires, Buenos Aires 1119, Argentina
  • Hospital Italiano de Buenos Aires
    Ciudad Autonoma de Buenos Aires, Buenos Aires 1181 ACH, Argentina
  • LUMIPIEL - Centro Dermatológico
    Ciudad Autonoma de Buenos Aires, Buenos Aires 1181 ACH, Argentina
  • Buenos Aires Skin
    Ciudad de Buenos Aires, Buenos Aires C1055AAO, Argentina
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2009
First posted
Apr 24, 2009
Start
Feb 2009
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Oct 23, 2012
Last update
Dec 13, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00887484
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 24, 2009
Start date
Feb 2009
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Oct 23, 2012
Last update
Dec 13, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Benzoyl Peroxide · Clindamycin

Start the discussion